Evidence map›Paper›PMID 41691638›Full record

Observational studyClinical transplantation2026

Insights From Black Living Kidney Donors: An Interview Study on APOL1 Genetic Testing Experiences.

Ana S Iltis, Heidi A Walsh, Kari Baldwin, Tristan McIntosh, Sumit Mohan, Deirdre Sawinski, Melody S Goodman, James M DuBois

Abstract readObservational Study
In one paragraph

Observational study in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ana S IltisCenter For Bioethics, Health and Society and Department of Philosophy, Wake Forest University, Winston-Salem, North Carolina, USA.ORCID https://orcid.org/0000-0003-0624-3022
Heidi A WalshBioethics Research Center, Division of General Medicine and Geriatrics, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0001-9447-6496
Kari BaldwinBioethics Research Center, Division of General Medicine and Geriatrics, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Tristan McIntoshBioethics Research Center, Division of General Medicine and Geriatrics, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-1931-4793
Sumit MohanDivision of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA.ORCID https://orcid.org/0000-0002-5305-9685
Deirdre SawinskiDivision of Nephrology, Hypertension and Transplantation, Department of Medicine, Weill Cornell Medical College, New York, USA.ORCID https://orcid.org/0000-0001-7903-8295
Melody S GoodmanBiostatistics Department, School of Global Public Health, New York University, New York, New York, USA.ORCID https://orcid.org/0000-0001-8932-624X
James M DuBoisBioethics Research Center, Division of General Medicine and Geriatrics, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-3712-7051

Funding

Wake Forest APOLLO Scientific and Data Research CenterU01DK116041 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Nicholette D. Allred, BARRY Ira FREEDMAN · 2017 to 2026
$8.7M
Continuous Therapeutic Drug Monitoring of Antibiotics in CRRTR01DK126739 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOHAN, SUMIT · 2021 to 2024
$2.8M
Towards rapid measurement of antibiotics in critical care settingR01EB032910 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREMERS, SERGE, LIN, QIAO · 2022 to 2025
$2.7M
India - Factors of CKDu in Uddanam Study (India-FOCUS)U01DK130058 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Vivekanand Jha, Sumit Mohan · 2021 to 2026
$2.6M
5/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical CenterU01DK116066 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Sumit Mohan, Deirdre Sawinski · 2017 to 2026
$2.5M
Wake Forest Collaborative Application for an APOLLO Clinical CenterU01DK116040 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BARRY Ira FREEDMAN, Rasheed Adebayo Gbadegesin · 2017 to 2026
$2.2M
Identifying and exploring solutions to the ethical challenges of ApoL1 testing of donors with recent African ancestry through mixed methods research with stakeholdersR01MD014161 · NIMHD · WASHINGTON UNIVERSITY · PI DUBOIS, JAMES M, MOHAN, SUMIT · 2019 to 2021
$1.2M
NIBIB NIH HHS R01 EB032910NIDDK NIH HHS R01 DK126739NIDDK NIH HHS U01 DK116040NIDDK NIH HHS U01 DK116041NIDDK NIH HHS U01 DK116066NIDDK NIH HHS U01 DK130058NIH HHSNIMHD NIH HHS R01DK126739NIMHD NIH HHS R01EB032910NIMHD NIH HHS R01 MD014161NIMHD NIH HHS R01MD014161NIMHD NIH HHS U01DK116040NIMHD NIH HHS U01DK116041NIMHD NIH HHS U01DK116066NIMHD NIH HHS U01DK130058
6 · The paper itself

Abstract

RATIONALE AND

objectiveTransplant center practices regarding APOL1 testing of living kidney donor candidates vary. The experiences, beliefs, and preferences of living kidney donors who have undergone APOL1 testing can provide valuable insights for transplant programs to consider when developing APOL1 testing policies. STUDY

designIn-depth, semi-structured interviews with Black living donors (LDs) and potential LDs who underwent APOL1 genotyping during their donor evaluation to explore their experiences, beliefs, and motivations regarding APOL1 testing in the context of actual LD decision-making. SETTINGS &

participants31 Black people (24 self-identified non-Hispanic Black people and 7 Hispanic Black people) who were evaluated for living kidney donation, had APOL1 testing, and agreed to donate were interviewed via Zoom. ANALYTIC APPROACH: Thematic analysis of de-identified transcripts of semi-structured interviews.

resultsFour themes emerged from analysis of interviews: (1) Information and communication needs, concerns, and preferences: information that living donor candidates receive often does not meet their expectations or needs, some actual and eligible participants did not recall testing; (2) Decisions regarding APOL1 testing and results: a common concern is that testing could result in being unable to donate, and many participants believed that donor candidates should be involved in deciding whether to test and how to use the results; (3) Sharing results with kidney recipients: some participants believe that it is important to share APOL1 status with intended recipients to help them make informed decisions; (4) Race and APOL1 testing: some participants expressed concern with using race as a basis for APOL1 testing. Transplant programs can use these results to inform their APOL1 testing policies and practices. LIMITATIONS: Most participants who were told and remembered their APOL1 status had a lower-risk genotype; people with higher-risk genotypes might hold different views. We were unable to verify self-reported APOL1 results. All participants were enrolled in the APOLLO study and were willing to be re-contacted to participate in research. Recall bias could have affected our findings because of the time that elapsed between testing and the interview.

conclusionMajor themes emerging from interviews were consistent with previous research and focused on the need for more transparent information sharing with prospective donors and the importance of autonomy and shared decision-making. PLAIN LANGUAGE SUMMARY: Potential living kidney donors who are identified as Black or African American sometimes undergo APOL1 genetic testing. The experiences, beliefs, and preferences of living kidney donors who have undergone APOL1 testing can provide valuable insights for transplant programs to consider when developing APOL1 testing policies. We interviewed 31 self-identified Black people who had APOL1 testing and were evaluated to be living kidney donors. We found that (1) they often wanted more information than they recieved; (2) many people think that potential donors should help to decide whether to get tested and how to use their results; (3) some people believe that potential kidney recipients should have access to their donor's APOL1 results; and (4) using race as the basis for testing raises concerns. We identify some implications our findings may have for transplant programs as they develop their APOL1 testing policies.

Indexed as

Apolipoprotein L1Black or African AmericanGenetic TestingKidney TransplantationLiving DonorsAdultDecision MakingFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisAPOL1 protein, humanApolipoprotein L1kidney transplantation: living donor, ethnicityrace, ethics, genetics

Identifiers

PMID41691638
PMCPMC12906861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.